loe-exposure
Drug patent expiries ranked by the Medicare Part D spending exposed to them
我该使用它吗
质量与安全性
A
基于对工具定义和协议合规性的自动分析。
上下文开销
~180token 数（工具定义）
~606 B典型响应大小
对注意力的影响极小（占 128k 上下文窗口的 0.14%）
这是每次将服务器的工具加载到模型上下文窗口时所消耗的大致 token 数。数值越高，可用于其他任务的注意力就越少。
安装
一键安装
将以下内容添加到你的 `claude_desktop_config.json` 文件中：
{
"mcpServers": {
"loe-exposure": {
"url": "https://rxfinder.ai/mcp"
}
}
}远程端点
https://rxfinder.ai/mcpstreamable-http它能做什么
工具清单
工具（1）
🟢 只读🟡 写入🔴 删除⚪ 未知
🟢loss_of_exclusivity_exposure(window, limit)
Rank upcoming FDA Orange Book patent and exclusivity expiries BY the gross Medicare Part D spending exposed to them, with marketed-generic status for each ranked drug resolved from live CMS NADAC price evidence. Answers which expiries matter, not merely which come first. Reports EXPOSURE, never forecast savings. Spending is gross of manufacturer rebates. Orange Book small molecules only, so biologics — among the largest Part D line items — are excluded, and the headline total must not be read as spending that will "go generic".
输入模式
{
"type": "object",
"properties": {
"window": {
"type": "string",
"description": "Months ahead to include, default 24"
},
"limit": {
"type": "string",
"description": "How many drugs to rank, default 25"
}
},
"required": []
}社区
证据
最近观测
已验证未记录版本1 个工具
已验证未记录版本1 个工具